2024: Wall Street’s Top and Bottom Performing Stocks

shares of common stock plus milestone payments, royalties, and the assumption of some development and commercialization costs. Alexion received the first payment December 7 after Monopar validated the license agreement.
 
#3. Myndlift
NASDAQ: MYND
2024 Increase: +1,209%
Stock prices for Myndlift surged 589% from $3.50 to $24.06 November 5, after the developer of personalized EEG-based neurofeedback solutions for ADHD and other neuropsychiatric conditions said it partnered with TELAVI on a joint venture to develop and market integrative therapies that combine Myndlift’s digital therapeutics with TELAVI’s neuro-cognitive training services. The joint venture is intended to address neurodevelopmental disorders, starting with ADHD and disorders with symptoms of poor focus and concentration, impulsivity, and hyperactivity. TELAVI combines non-invasive neurostimulation headbands with personalized tele-therapy, offering cognitive assessments performed by psychologists or neuroscientists. Myndlift and TELAVI collaborated to design customized headbands, with the goal of offering personalized and adaptive therapy solutions.
 
#4. Vivreon Biosciences
NASDAQ: VNCS
2024 Increase: +952%
As they diversified from its initial use as neuroimaging agents, Vivreon Bioscijsonances surged 406% from 48 cents to $2.43 on October 10, after the National Institute on Drug Abuse (NIDA) said their imaging probes held potential not only to track brain changes in drug users, but also to prevent opioid-overdose deaths by identifying users at risk for respiratory depression. Vivreon’s Positron Emission Tomography (PET) radioligands were developed to image novel neuroreceptors that have been genetically modified to express a fluorescent reporter protein. Some of the companies collaborating on the imaging agents with Vivreon were large pharma companies with development interests in addiction and other mental health disorders.
 
#5. X-Clinical
NASDAQ: XCLN
2024 Increase: +901%
X-Clinical found every reason to celebrate October 23 when the share price rose by 433% to $24.05. This jump came after the company revealed that X-Chem, its drug discovery division, had discovered molecules blocking a previously untargeted protein-protein interaction, with therapeutic potential in oncology and inflammation. X-Chem used its DEX platform—a drug discovery engine that combines DNA-encoded libraries with surface plasmon resonance for high-throughput screening—to identify first-in-class small molecules that disrupt the protein-protein interaction. The molecules had potency and selectivity enabling cellular target engagement, rapid mechanism of action, and in vivo pharmacokinetics suitable for further optimization.
 
Top 5 Stock Laggards
 
#1. Medipower Labs
NASDAQ: MPLB
2024 Decrease: -75%
The low point for Medipower was on April 3 at $1.21, down 30% from $1.73 at the outset of the year and a 78% nose dive from its high of $5.46 on January 23. Following the negative trend was the company’s announcement that Medipower would reveal detailed analyses from a failed Phase II trial. The trial assessed the efficacy of its lead candidate MP101 in patients with non-small-cell lung cancer who had progressed on targeted therapy or immunotherapy. Despite the trial’s failure, Medipower vowed to continue with MP101 development, after analyzing the trial’s extensive biomarker data.
 
#2. Cyterix Pharmaceuticals
NASDAQ: CYTX
2024 Decrease: -65%
Cyterix suffered its biggest stock drop October 29, falling to $2.68—down 44% from $4.82 at the outset of the year. The share price had hit the high point of $6.70 back on January 8. The plunge came on the heels of the company’s announcement that it had discontinued further development of its Phase II-ready candidate CYX-1503, after revealing disappointing data from preclinical models of bone cancer and inflammatory skin disorders. However, the company quickly pivoted, launching a Phase II trial of CYX-1503 in chronic pain, based on data from earlier clinical trials.
 
#3. Transurogenesis
NASDAQ: TRAN
2024 Decrease: -62%
After starting 2024 at $2.98, Transurogenesis plunged 54% November 12 to $1.38. A major factor was the company’s Phase II-ready candidate, a cell therapy for end-stage renal disease, failed to meet survival targets in a Phase II clinical trial. The stock had previously reached its high point of $5.18 on January 18. Following the setback, Transurogenesis planned to repurpose the cell therapy as a potential treatment for acute kidney injury (AKI),